Non-dilutive first: the grants medtech founders miss

Device companies get diluted harder than software companies. Carta's 2026 founder ownership data puts median founder ownership at Series A at 37.5% for digital businesses and 30.5% for physical ones — a seven-point penalty for building something you have to manufacture, validate and certify. Median founder ownership falls from roughly 56% after seed to 36% at Series A, and by Series C the median employee option pool is larger than the median founder stake.

Every month of runway you buy without selling equity is bought at the cheapest price you will ever pay. And in medtech, the grant landscape is unusually generous — because regulators, health systems and governments all have an interest in the thing you are building existing. The problem is that the landscape moves constantly, most published advice is out of date, and the programmes founders name from memory are frequently the ones that closed.

Here is the honest state of it in August 2026, for European, UK and Singapore-based medtech.

What is actually open right now

Start here, because deadlines are the binding constraint. Everything below was open as at 12 August 2026.

Four things founders get wrong

1. Innovate UK Smart Grants are still paused

This is the single most common out-of-date assumption in UK founder funding conversations. Innovate UK paused new Smart Grants competitions in January 2025 and, as at August 2026, they have not returned. The redesign ties future support to the UK's Modern Industrial Strategy, which means any successor is likely to be narrower and sector-targeted rather than the open, sector-agnostic fund people remember.

What replaced it in practice is the Growth Catalyst family — most usefully Investor Partnerships, where life sciences including medical technologies and health data/AI are explicitly in scope. Grant rates run to 70% for micro and small companies on feasibility and industrial research, 45% on experimental development, with project cost bands from £50k up to £2m. The catch is structural: you need a confirmed investor partner committing aligned investment before you apply — at least matching the grant, and at least double it for experimental development. Round 2 closed in February 2026; a Round 3 has not been announced but the cadence suggests one.

The Biomedical Catalyst remains the most medtech-specific UK route, with £140m committed across the current spending review period covering devices and digital health as well as therapeutics. The 2025 industry-led round ran grants of £150k–£500k for small projects at intervention rates up to 70% for micro and small companies. A 2026 round has not been announced as of mid-August; historically it opens in autumn, so prepare rather than wait.

2. UK companies cannot take EIC equity

The EIC Accelerator is described everywhere as "up to €12.5m blended finance". For a UK applicant that number is wrong. The UK is associated to Horizon Europe for grants but is excluded from the EIC Fund's equity instrument — so the realistic ceiling for a UK SME is the €2.5m grant component only. That is still an excellent outcome; it is just a different plan from the one the headline implies.

Two other things changed for 2026 that materially affect how you approach it. There are now six full-proposal cut-offs a year instead of two, which makes the Accelerator a schedulable event rather than an annual lottery. And the full proposal is capped at 20 pages, with remote technical interviews and technical due diligence added at the full-proposal stage. Health remains a top-3 funded sector — around a quarter of winners in the first 2026 cut-off — but note that none of the 2026 Accelerator Challenge topics are health or medtech, so medtech goes through Accelerator Open.

3. Eurostars is the one programme that spans Europe and Singapore

This is the most under-used hook in the whole landscape for companies with a foot in both regions. Eurostars covers 36 countries — the EU and associated states plus Canada, Israel, South Korea, South Africa and Singapore. It is the one instrument where a UK or EU medtech and a Singapore partner can be funded inside the same consortium, on the same project.

The requirements are modest by EU standards: two independent entities from two Eurostars countries, led by an innovative SME, SME budgets at least half the total, maximum 36 months. Funding is national rather than central, so rates differ by country — UK participants get up to €360,000 at up to 60% of eligible costs through Innovate UK, and note that only UK SMEs are funded; there is no UK budget for universities or large companies in this scheme. Call 11 closes 10 September 2026.

4. Singapore's health grants mostly go to hospitals, not companies

Founders arriving in Singapore expect a company-facing grant system and find something structurally different. The two most substantial health innovation instruments — NHIC's Innovation to Develop and NMRC's Clinical Trial Grant — are awarded to public institutions, with a principal investigator holding a salaried appointment at a Singapore public healthcare institution.

• NHIC I2D — S$400,000 over up to 18 months, awarded to the host institution on a reimbursement basis, for development towards clinical and market readiness. Industry collaboration is encouraged but the PI must be a public-sector clinician. Calls typically open in January and July.
• NMRC Clinical Trial Grant (Industry Collaborative Trials) — up to 30% of total project costs, capped at S$4.94m per project. Companies cannot apply directly but can participate as the industry partner, contributing funding and intellectual input. In effect, the state co-funds roughly a third of a Singapore clinical trial you run with a public hospital.

The strategic read is simple: in Singapore, your access route to public health innovation capital is a clinical partnership, not an application form. Pick the institution and the clinician champion first; the funding follows the collaboration.

The Singapore instruments you apply for directly

Worth knowing for context: Singapore committed S$37 billion to RIE2030, announced in December 2025 — a 32% increase on RIE2025 — with "Human Health and Potential" as one of four core domains and an explicit ambition to build the country as a biomedtech hub. Startup SG Equity, the state co-investment vehicle, received a S$1 billion top-up in 2026 and co-invests up to S$12m in deep tech including medtech. That is dilutive capital, but it is matched state money on published ratios, which makes it a useful benchmark when pricing a private round.

What quietly closed

Half of good funding advice is knowing what to stop chasing. As at August 2026, the following are closed, paused or superseded:

• Innovate UK Smart Grants — paused since January 2025, not reinstated.
• Horizon Europe Cluster 1 (Health) 2026 calls — closed 16 April 2026. These are large multi-country consortia on four-to-five-year timelines: partner-slot opportunities, not runway extension for a seed-stage company.
• Innovative Health Initiative Call 12 — closed 21 April 2026 (€163.1m across five topics, with at least 45% of project budget required as industry contribution).
• EU4Health 2026 calls — closed 6 January 2026. The programme is overwhelmingly aimed at national authorities and health organisations rather than commercial SMEs, and runs to 2027.
• NIHR i4i PDA, FAST and THRIVE spring 2026 calls — all closed. i4i runs roughly twice yearly; i4i Connect (£50k–£150k for UK SMEs) has not announced a new round.
• EIC Pre-Accelerator — no 2026 call; next opens 2027, and it is limited to widening countries.

One live planning risk worth naming: the successor to Horizon Europe under the 2028–2034 budget is still being negotiated, with Council agreeing only a partial position in June 2026. The budget is unsettled and UK association to the post-2027 programme is not agreed. If your funding plan depends on EU grants in 2028 and beyond, treat that as an open question rather than a base case.

Sequencing a non-dilutive plan

Grants reward companies that treat them as a pipeline rather than a rescue. A workable ladder for a European or UK medtech:

1. Pre-prototype / TRL 2–4. University-partnered translational funding (MRC, BBSRC proof-of-concept) and EIC Pathfinder if you have a consortium. Accept that these route through a research organisation.
2. Prototype to first clinical evidence / TRL 4–6. Biomedical Catalyst, NIHR i4i, Eurostars with an international partner, EIC Transition if you hold a qualifying prior grant. This is where the densest medtech-specific money sits.
3. Regulatory and market entry / TRL 6–8. EIC Accelerator, EIT Health Innovation Uptake — the latter is unusual and underrated in that it funds health economics and reimbursement pathway work, which is exactly what most founders underfund and what most investors ask about.
4. NHS or health-system adoption. SBRI Healthcare contracts, which are 100% funded, take no equity and transfer no IP.
5. Singapore entry. Startup SG Tech and EDG directly; NHIC and NMRC via a public hospital partnership established well in advance.

What grants actually cost

They are not free money, and pretending otherwise leads teams into bad decisions. The real costs are co-funding (most schemes fund 50–70%, so you need matched cash), timeline (three to nine months from application to first disbursement is normal, and reimbursement basis means you spend first), reporting overhead, and scope rigidity — the project you described is the project you must deliver. US data offers a useful calibration on odds: fewer than one in five SBIR/STTR applicants were funded over the last decade.

The genuine strategic advantage is subtler than the cash. As Goodwin puts it, non-dilutive funding "engenders external support, maintains founders' ownership, and postpones valuation". That last point is the one to internalise. A grant that carries you nine months further into your clinical evidence before you price a round is worth considerably more than its face value — provided you spend those nine months generating the evidence that moves the valuation, not writing the next application.